Empagliflozin improves survival in type 2 diabetes patients with established cardiovascular diseaseEstimated to improve life expectancy by one to 4.5 years according to an analysis of data from a major trial Watch for lung cancer risk in patients taking ACE inhibitors Study questions clinical guidelines for antihypertensive treatment Methotrexate underperforms as an alternative for lowering inflammation linked to cardiovascular events Study shows little heart help from Vitamin D, omega-3 5 tips for interpreting home blood pressure measurements Invokana now indicated to reduce the risk of major cardiovascular events Health Canada approves new tests for diagnosing heart attacks faster Two innovative assays that can shorten the time required to diagnose life-threatening heart attacks have been licensed for sale by Health Canada. Bariatric surgery may reduce risk of macrovascular events in severely obese type 2 diabetes patients Insurance coverage for weight loss surgeries should be expanded for appropriate patients 2018 Consolidated Canadian guideline for preventing and managing cardiovascular disease in primary care C-CHANGE guideline combines recommendations from nine Canadian cardiovascular-related guidelines to meet primary care needs First Previous 32 33 34 35 36 Next Last
